AZNAstraZenecaSigning up patients
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 800 (planned)
- Started
- Sep 22, 2023
- Main results expected
- Nov 26, 2027
- Fully finished
- Sep 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS)
Measured over: Up to approximately 7 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06079671 · record last updated 2026-09-30 · checked 2026-11-09 15:47 UTC